Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × abexinostat × 1 year × Clear all
NCT05698524 2026-04-17

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

University of Nebraska

Phase 1 Recruiting
24 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01027910 2025-07-24

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Massachusetts General Hospital

Phase 1/2 Completed
20 enrolled 10 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡